Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (7): 2940-2941.doi: 10.4103/NRR.NRR-D-25-00651

Previous Articles     Next Articles

FKBP51: A new target for Parkinson’s disease

Marta Garcia-Gomara, Mar Cuadrado-Tejedor*, Ana Garcia-Osta*   

  1. Gene Therapy for CNS Disorders program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
    IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
    Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
  • Online:2026-07-15 Published:2026-03-27
  • Contact: Ana Garcia-Osta, PhD,agosta@unav.es; Mar Cuadrado-Tejedor, PhD,mcuadrado@unav.es.
  • Supported by:
    This work was supported by PID2022-138285OB-I00, financiado por MCIN/AEI/10.13039/501100011033/FEDER, UE to AGO and MCT, and by Asociación de Amigos fellowship grant to MGG.

PDF

52

Abstract: Parkinson’s disease (PD) is a progressive age-related neurodegenerative disorder clinically defined by motor symptoms and pathologically by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. These neurons are characterized by the presence of the cytoplasmic pigment neuromelanin (NM), and their degeneration is closely associated with the accumulation of α-synuclein (α-syn) into intraneuronal inclusions known as Lewy bodies (LBs), which represent a neuropathological hallmark of PD.